Healthcare >> CEO Interviews >> October 1, 2001
R. DOUGLAS ARMSTRONG is Chief Executive Officer and Chairman of Aastrom
Biosciences, Inc. He joined Aastrom in June 1991 as its President and
Chief Executive Officer, and as a Director. In 1999, Dr. Armstrong was
elected Chairman of Aastron's Board of Directors. In July 2004, the
duties and responsibilities of President were transferred to the
company's new Chief Operating Officer, allowing Dr. Armstrong, as CEO,
to increase focus on strategic activities and issues, investor
relations, the Board of Directors, and Aastron's European subsidiary,
Zellera AG, for which he is also Chairman of the Supervisory Board. From
1987 to 1991, Dr. Armstrong served as Executive Vice President and
Trustee at the La Jolla Cancer Research Foundation (LJCRF), now named
the Burnham Institute, a scientific research institute located in San
Diego, California. Prior to joining the Burnham Institute, Dr. Armstrong
held various faculty and staff positions at the Yale University School
of Medicine, University of California, San Francisco, LJCRF and the
University of Michigan. Dr. Armstrong received a Bachelor of Arts degree
in Chemistry from the University of Richmond in Richmond, Virginia, and
completed his Doctorate in Pharmacology and Toxicology from the Medical
College of Virginia. Additionally, Dr. Armstrong was a participant in
the formation of Telios Pharmaceuticals, Inc., has served on the Boards
of both biotechnology companies and a venture capital fund, and
currently serves as the Chairman of the Board for the Center for Cell
Therapy. Profile
then an overview or a picture of the company as it is now?
Dr. Armstrong: Aastrom is a leading developer of innovative
